1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - From genetics to therapeutics in Alzheimer’s: accelerating translation, increasing success"}],["$","meta","1",{"name":"description","content":"Dr. Mucke’s research focuses on conditions that cause cognitive deficits, behavioral abnormalities and other major neurological alterations, including aging-related dementias, epilepsy and neuropsychiatric disorders. He uses transgenic mouse models and neural cultures to dissect the pathogenic pathways that lead from genetic and environmental risk factors to neurological abnormalities at the molecular, cellular, network and behavioral level. Experimental models are also used to develop and evaluate novel treatment strategies. The clinical relevance and potential impact of the models and therapeutic strategies is then assessed in studies of human subjects.

For more information go to https://oir.nih.gov/wals/2017-2018/genetics-therapeutics-alzheimers-accelerating-translation-increasing"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - From genetics to therapeutics in Alzheimer’s: accelerating translation, increasing success"}],["$","meta","4",{"property":"og:description","content":"Dr. Mucke’s research focuses on conditions that cause cognitive deficits, behavioral abnormalities and other major neurological alterations, including aging-related dementias, epilepsy and neuropsychiatric disorders. He uses transgenic mouse models and neural cultures to dissect the pathogenic pathways that lead from genetic and environmental risk factors to neurological abnormalities at the molecular, cellular, network and behavioral level. Experimental models are also used to develop and evaluate novel treatment strategies. The clinical relevance and potential impact of the models and therapeutic strategies is then assessed in studies of human subjects.

For more information go to https://oir.nih.gov/wals/2017-2018/genetics-therapeutics-alzheimers-accelerating-translation-increasing"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/b4e2841e-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/f1502d19-b955-4862-aedd-cb2dae99a9ce.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - From genetics to therapeutics in Alzheimer’s: accelerating translation, increasing success"}],["$","meta","11",{"name":"twitter:description","content":"Dr. Mucke’s research focuses on conditions that cause cognitive deficits, behavioral abnormalities and other major neurological alterations, including aging-related dementias, epilepsy and neuropsychiatric disorders. He uses transgenic mouse models and neural cultures to dissect the pathogenic pathways that lead from genetic and environmental risk factors to neurological abnormalities at the molecular, cellular, network and behavioral level. Experimental models are also used to develop and evaluate novel treatment strategies. The clinical relevance and potential impact of the models and therapeutic strategies is then assessed in studies of human subjects.

For more information go to https://oir.nih.gov/wals/2017-2018/genetics-therapeutics-alzheimers-accelerating-translation-increasing"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}